(AVTR) Avantor - Ratings and Ratios
Materials, Consumables, Equipment, Services
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 48.1% |
| Value at Risk 5%th | 63.7% |
| Relative Tail Risk | -19.49% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.83 |
| Alpha | -63.64 |
| CAGR/Max DD | -0.28 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.391 |
| Beta | 1.115 |
| Beta Downside | 1.016 |
| Drawdowns 3y | |
|---|---|
| Max DD | 61.62% |
| Mean DD | 24.70% |
| Median DD | 18.67% |
Description: AVTR Avantor January 06, 2026
Avantor, Inc. (NYSE:AVTR) supplies mission-critical products and services across biopharma, healthcare, education, government, advanced-technology, and applied-materials markets worldwide, operating in the Americas, Europe, Asia, the Middle East, and Africa.
The company’s catalog includes high-purity chemicals and reagents, lab consumables, formulated silicone materials, custom excipients, single-use assemblies, chromatography resins and columns, analytical sample-prep kits, microbiology products, clinical-trial kits, and fluid-handling tips.
In addition to consumables, Avantor offers equipment such as filtration and virus-inactivation systems, incubators, analytical instruments, ultra-low-temperature freezers, biosafety cabinets, peristaltic pumps, and related critical-environment supplies, plus on-site services ranging from lab and production support to procurement, scale-up, and biopharmaceutical development.
Key metrics (as of FY 2023) show revenue of roughly $13.5 billion, a 9 % YoY growth rate driven largely by expanding demand for single-use bioprocessing solutions and the resurgence of vaccine manufacturing, and an adjusted EBITDA margin near 15 %. The life-sciences tools sector benefits from a projected 8 % CAGR through 2028, underpinned by rising biologics pipelines, tighter regulatory scrutiny on contamination control, and sustained government spending on health-security infrastructure.
For a deeper, data-driven assessment of Avantor’s valuation dynamics, you might find ValueRay’s analytical platform worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (-82.2m TTM) > 0 and > 6% of Revenue (6% = 394.5m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA -1.33pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 11.27% (prev 12.83%; Δ -1.56pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 644.4m > Net Income -82.2m (YES >=105%, WARN >=100%) |
| Net Debt (3.61b) to EBITDA (644.6m) ratio: 5.59 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.49 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (681.7m) change vs 12m ago -0.19% (target <= -2.0% for YES) |
| Gross Margin 33.13% (prev 33.53%; Δ -0.40pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 53.64% (prev 53.11%; Δ 0.53pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.36 (EBITDA TTM 644.6m / Interest Expense TTM 174.7m) >= 6 (WARN >= 3) |
Altman Z'' 1.96
| (A) 0.06 = (Total Current Assets 2.26b - Total Current Liabilities 1.52b) / Total Assets 11.68b |
| (B) 0.14 = Retained Earnings (Balance) 1.62b / Total Assets 11.68b |
| (C) 0.02 = EBIT TTM 236.8m / Avg Total Assets 12.26b |
| (D) 0.91 = Book Value of Equity 5.57b / Total Liabilities 6.11b |
| Total Rating: 1.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 35.44
| 1. Piotroski 3.50pt |
| 2. FCF Yield 4.59% |
| 3. FCF Margin 7.96% |
| 4. Debt/Equity 0.69 |
| 5. Debt/Ebitda 5.59 |
| 6. ROIC - WACC (= -4.74)% |
| 7. RoE -1.38% |
| 8. Rev. Trend -93.01% |
| 9. EPS Trend -79.74% |
What is the price of AVTR shares?
Over the past week, the price has changed by +6.97%, over one month by +14.57%, over three months by -12.92% and over the past year by -44.02%.
Is AVTR a buy, sell or hold?
- Strong Buy: 6
- Buy: 4
- Hold: 11
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the AVTR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13.3 | 8.6% |
| Analysts Target Price | 13.3 | 8.6% |
| ValueRay Target Price | 10.1 | -18% |
AVTR Fundamental Data Overview January 04, 2026
P/E Forward = 12.0192
P/S = 1.1883
P/B = 1.4028
Beta = 0.93
Revenue TTM = 6.58b USD
EBIT TTM = 236.8m USD
EBITDA TTM = 644.6m USD
Long Term Debt = 3.64b USD (from longTermDebt, last quarter)
Short Term Debt = 219.8m USD (from shortTermDebt, last quarter)
Debt = 3.86b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.61b USD (from netDebt column, last quarter)
Enterprise Value = 11.42b USD (7.81b + Debt 3.86b - CCE 251.9m)
Interest Coverage Ratio = 1.36 (Ebit TTM 236.8m / Interest Expense TTM 174.7m)
FCF Yield = 4.59% (FCF TTM 523.6m / Enterprise Value 11.42b)
FCF Margin = 7.96% (FCF TTM 523.6m / Revenue TTM 6.58b)
Net Margin = -1.25% (Net Income TTM -82.2m / Revenue TTM 6.58b)
Gross Margin = 33.13% ((Revenue TTM 6.58b - Cost of Revenue TTM 4.40b) / Revenue TTM)
Gross Margin QoQ = 32.42% (prev 32.92%)
Tobins Q-Ratio = 0.98 (Enterprise Value 11.42b / Total Assets 11.68b)
Interest Expense / Debt = 1.15% (Interest Expense 44.2m / Debt 3.86b)
Taxrate = -3.23% (negative due to tax credits) (22.3m / -689.5m)
NOPAT = 244.5m (EBIT 236.8m * (1 - -3.23%)) [negative tax rate / tax credits]
Current Ratio = 1.49 (Total Current Assets 2.26b / Total Current Liabilities 1.52b)
Debt / Equity = 0.69 (Debt 3.86b / totalStockholderEquity, last quarter 5.57b)
Debt / EBITDA = 5.59 (Net Debt 3.61b / EBITDA 644.6m)
Debt / FCF = 6.89 (Net Debt 3.61b / FCF TTM 523.6m)
Total Stockholder Equity = 5.98b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.70% (Net Income -82.2m / Total Assets 11.68b)
RoE = -1.38% (Net Income TTM -82.2m / Total Stockholder Equity 5.98b)
RoCE = 2.46% (EBIT 236.8m / Capital Employed (Equity 5.98b + L.T.Debt 3.64b))
RoIC = 2.43% (NOPAT 244.5m / Invested Capital 10.04b)
WACC = 7.17% (E(7.81b)/V(11.67b) * Re(10.13%) + D(3.86b)/V(11.67b) * Rd(1.15%) * (1-Tc(-0.03)))
Discount Rate = 10.13% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.22%
[DCF Debug] Terminal Value 69.39% ; FCFE base≈613.0m ; Y1≈562.3m ; Y5≈502.0m
Fair Price DCF = 9.46 (DCF Value 6.45b / Shares Outstanding 681.8m; 5y FCF grow -10.37% → 3.0% )
EPS Correlation: -79.74 | EPS CAGR: -52.18% | SUE: -4.0 | # QB: 0
Revenue Correlation: -93.01 | Revenue CAGR: -4.20% | SUE: -1.36 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.20 | Chg30d=-0.002 | Revisions Net=+0 | Analysts=15
EPS next Year (2026-12-31): EPS=0.91 | Chg30d=+0.001 | Revisions Net=+0 | Growth EPS=+1.1% | Growth Revenue=+0.1%
Additional Sources for AVTR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle